ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?

M. Ravindranath, P. Terasaki, C. Maehara, V. Jucaud.

HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.

Meeting: 2015 American Transplant Congress

Abstract number: A92

Keywords: HLA antibodies, HLA antigens, IVIG, Monitoring

Session Information

Session Name: Poster Session A: Kidney Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which anti-HLA-I & -II IgG occur in IVIg preparations used to lower HLA IgG in pre- and post-transplant patients are not evaluated. Possibly this is the reason for failure of IVIg to lower anti-HLA IgG in sensitized patients. Also, high titers of anti-HLA-I/-II IgG in IVIg may place transplant patients at risk for endothelial damage as observed in patients and animal models of “IVIg-transfusion-related acute lung injury”.

Herein, we analyzed the commercial preparations of IVIg and sera of non-alloimmunized males & renal transplant patients for (1) HLA-Ia & Ib reactivity, (2) HLA-II reactivity, (3) IgG isotype characterization using Luminex®-based immunoassay. Reliability of secondary antibodies targeting H & L chains of IgG (One Lambda, Inc) and Fcγ2AB domain (S. Biochem) was examined for monitoring of anti-HLA IgG.

IVIg preparations and the purified-IgG and the native sera showed that HLA-IgG antibodies occur in the following order of frequency: DPA (80%), DQA (71%), DRB345 (67%), DQB (57%), Cw (50%), DBP (43%), DRB1 (21%), A (14%), and B (7%). Indeed, the therapeutic preparations of IVIg used for transplant patients had high titers of HLA-I/-II IgG, as follows: Gamastan = Gamunex < Octagam << Sandaglobulin. The highest titer of HLA-II IgG in different preparations of IVIg were observed against DRB3*03:01, DQA1*01:02DQB1*06:02 and DPA1*02:01/DPB1*23:01, exactly similar to that seen for the purified and native sera of all (n =15) healthy males. The anti-HLA IgG isotypes in IVIg, in purified and raw sera of non-alloimmunized males, as well as in allograft recipients differed in the following order:IgG1>IgG2a>IgG3>IgG4.

These results postulate the risks involved in transfusing IVIg for purpose of lowing HLA antibodies in sensitized patients and allograft recipients and stipulate reevaluating the use of IVIg in transplantation. If IVIg is used for transplantation, whether at low or high doses, the IVIg preparation should be assessed prior to use for the profile and titers of anti-HLA-I/-II IgG. Preferably the HLA-reactivity of IVIg should be examined in the context of molecular HLA typing of recipients and donors.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Ravindranath M, Terasaki P, Maehara C, Jucaud V. Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients? [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/should-current-ivig-preparations-containing-high-titers-of-anti-hla-i-ii-igg-be-used-for-lowering-the-anti-hla-igg-in-sensitized-pre-transplant-patients-and-allograft-recipients/. Accessed May 28, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences